The latest: Zai Lab Ltd. (9688.HK,ZLAB.US), a biotech company with a primary listing in New York and secondary listing in Hong Kong, announced on Tuesday that it has received approval to elevate its Hong Kong listing to primary status. It said it expects the conversion to become effective on June 27.

Looking up: The company believes the upgrade will help attract more investors to its Hong Kong-listed stock, thereby expanding its investor base and trading volume.

Take Note: Unlike secondary listings, dual-primary listings are subject to higher regulatory requirements and do not enjoy the same leniency and exemptions from the Hong Kong Stock Exchange.

Digging Deeper: The U.S. passed the Holding Foreign Companies Accountable Act (HFCAA) in 2020, empowering the U.S. securities regulator to suspend or even delist foreign companies that do not meet U.S. disclosure requirements. Since then, Zai Lab’s U.S.-listed shares were identified by the regulator in March for potential delisting, after which the company chose to change its Hong Kong listing status to primary from its previous secondary status. That means both capital markets will become the company’s primary listing venues, and that the company’s Hong Kong listing status would not be affected even if its shares were later delisted in the U.S.

Market Reaction: Zai Lab’s U.S. shares fell 2.7% to $29.10 on Tuesday. Its Hong Kong shares plunged 6.6% to HK$23.25 at the midday break on Wednesday, nearing a 52-week low.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

So-Young dolls up with move to high-end cosmetic surgery

So-Young dolls up with pivot to high-end services

The cosmetic services social media platform is developing its own clinics as well as a premium platform for high-end users Key Takeaways: So-Young reported an annual profit last year, reversing…

NEWS WRAP: Nayuki pours up first annual profit

The premium tea chain aims to expand through franchising to boost its growth amid intense competition  By Teri Yu  Premium tea seller Nayuki Holdings Ltd. (2150.HK) on Wednesday reported its first annual profit since…
Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs.

Akeso marks profit milestone with swift rights issue

Buoyed by bumper earnings, the biotech has announced a share placement to raise HK$1.17 billion to invest in developing its portfolio of anti-cancer drugs Key Takeaways: Akeso swung to an…